Investment Stage: Series C
Portfolio 11
| Date | Name | Website | Total Raised | Location |
| 28.03.2017 | Antiva Bio... | antivabio.... | $137M | United Sta... |
| - | Precision ... | precisionb... | $135.6M | United Sta... |
| - | VERO Biote... | vero-biote... | $80M | United Sta... |
| - | F2G | f2g.com | $191M | United Kin... |
| - | Turnstone ... | turnstoneb... | $132.7M | United Sta... |
| - | ReViral | reviral.co... | $99M | United Kin... |
| - | Gliknik | gliknik.co... | $124.4M | United Sta... |
| - | Zymeworks ... | zymeworks.... | $514.6M | Canada, Br... |
| - | AVROBIO | avrobio.co... | $85M | United Sta... |
| - | Avidity Bi... | aviditybio... | $201M | United Sta... |
Show more
Mentions in press and media 4
| Date | Title | Description | Source |
| 28.03.2017 | Brace Pharma Capital Leads $22M Series C for Antiva Bioscien... | Antiva Biosciences, a biopharmaceutical company developing novel, topical therapeutics for the treat... | citybizlis... |
| 18.11.2015 | Therabron gets $6.75M for drug that helps premature babies b... | The company’s lead compound, CG100, is based on recombinant human CC10 secretoglobins – proteins mea... | medcitynew... |
| 19.06.2014 | Tyrogenex Receives $15M in Series D Financing | Tyrogenex Inc., a West Palm Beach, FL-based Xcovery Group company focused on discovering and develop... | finsmes.co... |
| - | Therabron gets $6.75M for drug that helps premature babies b... | It’s quite common for premature infants to have difficulty breathing – in fact, it’s a leading cause... | medcitynew... |